Inflammatix, Inc.

Inflammatix, Inc.

We’re reimagining diagnostics by reading the immune system

Founded 2016

Sunnyvale, United States 96 employees Grant Total: $137.80M Big Data, Biotechnology +2

Inflammatix, Inc. is a U.S.-based startup that is revolutionizing diagnostics through its innovative approach of tapping into the immune system. Founded in 2016, the company's mission is reflected in its slogan "We're reimagining diagnostics by reading the immune system." Inflammatix is focused on developing a pioneering point-of-care instrument platform that works in conjunction with a test to facilitate the diagnosis of acute infection and sepsis by leveraging advanced immune response diagnostics. This breakthrough technology is designed to rapidly provide clinicians with crucial information about the likelihood of bacterial or viral infection, as well as the necessity for ICU level care in emergency departments. The faster results delivered by the platform have the potential to lead to more prompt and suitable therapy, as well as decisions regarding the level of care required. In November 2021, the company received a significant grant investment of $1.70M from the National Institutes of Health. It's important to note that the products developed by Inflammatix are still in the developmental phase and have not yet received marketing approval or regulatory clearance in any jurisdiction. With its focus on big data, biotechnology, and healthcare, Inflammatix is poised to continue making strides in the field of diagnostics and providing critical solutions for acute infections and sepsis.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	$1.70M	1	National Institutes of Health	11 Nov 2021
Series D	$102.00M	6	D1 Capital Partners, Khosla Ventures +4	16 Mar 2021
Grant	$1.10M	1	DARPA	29 Sep 2020
Series C	$32.00M	4	Khosla Ventures, Grey Sky Venture Partners +2	10 Jan 2020
Series B	Undisclosed	2	Northpond Ventures, Think.Health	18 Oct 2018
Series A	Undisclosed	2	Khosla Ventures, StartX	17 Mar 2017
Grant	$999.92K	1	DARPA	20 Jan 2017

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

$1.70M

National Institutes of Health

11 Nov 2021

Series D

$102.00M

D1 Capital Partners, Khosla Ventures +4

16 Mar 2021

Grant

$1.10M

DARPA

29 Sep 2020

Series C

$32.00M

Khosla Ventures, Grey Sky Venture Partners +2

10 Jan 2020

Series B

Undisclosed

Northpond Ventures, Think.Health

18 Oct 2018

Series A

Undisclosed

Khosla Ventures, StartX

17 Mar 2017

Grant

$999.92K

DARPA

20 Jan 2017

FAQ About Inflammatix, Inc.

We’re reimagining diagnostics by reading the immune system

Inflammatix, Inc. was founded in 2016.

Inflammatix, Inc. is headquartered in Sunnyvale, United States.

Inflammatix, Inc. operates in Big Data, Biotechnology, Health Care and Clean Energy. Its work centres on diagnostics, point-of-care testing, immune system and acute infection.

Inflammatix, Inc. has approximately 96 employees.

Inflammatix, Inc. has completed 7 funding rounds, raising a total of $137.80M. The latest funding stage is Grant.

Top alternatives and competitors to Inflammatix, Inc. include Immunexpress Inc., ARTCLINE GmbH, Response Biomedical Corp., Invirsa, Inc, Kantum Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Inflammatix, Inc. and Immunexpress Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Inflammatix, Inc.

Funding Rounds & Investors (7)

Inflammatix, Inc. Alternatives & Competitors

FAQ About Inflammatix, Inc.